Palbociclib, or Ibrance

Palbociclib, or Ibrance

This patient-friendly article is about chemotherapy drug, Palbociclib also known by its trade name Ibrance was approved by the FDA in 2015 for the use of treating breast cancer. The cancer drug produced by Pfizer is a kinase inhibitor used on patients with HR-positive, HER2-negative advanced or metastatic breast cancer. 

In 2018, it obtained U.S. sales of approximately $2.9 billion and a full-year revenue totalling $53.6 billion. In 2019 Pfizer totalled its biopharma revenues for the second quarter of the year which summed up to $9.6 billion.

Approved by

the Medical Board. 

Click Here

Palbociclib is used to block CDK4 and CDK6 proteins which are proteins responsible for the growth of cancer cells. It is used in combination with an aromatase inhibitor as the first treatment of hormonal therapy in postmenopausal women or men. Ibrance is also used in combination with fulvestrant for women or men who have had hormonal therapy before and their disease has progressed. 


The recommended dosage of Palbociclib in combination with an aromatase inhibitor or fulvestrant is 125 mg (orally) once a day for 21 days and then 7 days off. 

Common side effects include nausea, diarrhea, easily bruised, vomiting, infections, increased in body temperature, anaemia and experience of hair loss. 


  • Neutropenia (low concentration of a certain type of white blood cells)
  • Used during pregnancy can cause embryo-fetal toxicity.

Go to: 10 ways to improve your chemotherapy success and reduce side-effects

Other articles that you may find interesting are:

  1. A diet for Chemotherapy
  2. Immunotherapy overview
  3. A to Z Guide to Complementary Therapies

Go to: Return to the CANCERactive drug list


CANCERactive - the appliance of Science


Health Experts
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Chris'

Join Chris' NewsletterSignup today for free and be the first to get notified on new updates.